secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025241
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma appoints Greg Pyszcymuka to board as Class I director
------------------------------------------------------------------

- Appointed effective Feb 20, 2025; term expires at 2026 annual meeting.
- He is CCO of Aytu Biopharma (Nasdaq: AYTU); appointed under Nantahala Capital Management agreement (Sept 2024).
- Received options for 5,833 shares vesting equally over three years; also standard cash compensation.
- Compensation Committee: Hill (chair), Pyszcymuka, Brady; Nominating & Governance: Pyszcymuka, Widder, Hill (chair).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017025025241/0000950170-25-025241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017025025241/evok-20250220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer